<DOC>
	<DOCNO>NCT00936676</DOCNO>
	<brief_summary>Eligible participant , participate ADAGIO trial sign approve informed consent form , enrol study original study location . participant stop rasagiline therapy opinion investigator gain clinical benefit restart treatment also consider enrollment Core follow-up study period . Use anti-PD treatment permit deemed necessary treating physician ( accord participant clinical status ) .</brief_summary>
	<brief_title>ADAGIO Follow Up Study : Evaluation Long-Term Effects Rasagiline Parkinson 's Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>1 . Subjects participate ADAGIO study , enter active phase study 2 . Subjects currently rasagiline treatment ( subject stop rasagiline treatment , willing restart treatment , opinion investigator gain clinical benefit restart treatment ) 3 . Subjects diagnosis Parkinson 's disease 4 . Subjects willing able give write informed consent 1 . Subjects discontinue rasagiline treatment due adverse event restart rasagiline treatment subsequently . 2 . Subjects give rasagiline due exclusion base local label ( include pregnancy nurse woman ) due use medication contraindicate concomitant use rasagiline accord local label 3 . Subjects medical condition consider investigator significant enough prevent participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>parkinson 's</keyword>
	<keyword>long-term effect</keyword>
	<keyword>adagio</keyword>
	<keyword>rasagiline</keyword>
	<keyword>delay start</keyword>
</DOC>